Market Place
Sourcing Support
All News #Library
Biotech
Maze Pharma`s Q4 2025 Financials And Highlights Released
25 Mar 2026 //
GLOBENEWSWIRE
Maze Stock Plummets After Potential `Best-In-Class` Ph. 2 Data
25 Mar 2026 //
GLOBENEWSWIRE
Maze Pharma Joins Guggenheim Biotech Summit 2026
04 Feb 2026 //
GLOBENEWSWIRE
Maze Pharma Joins 44Th J.P. Morgan Healthcare Conference
05 Jan 2026 //
GLOBENEWSWIRE
Maze Pharma Reveals Q3 2025 Financials And Recent Achievements
06 Nov 2025 //
GLOBENEWSWIRE
Maze Pharma Names Hervé Hoppenot Chairman Of Board
06 Oct 2025 //
GLOBENEWSWIRE
Maze` Phase 1 Trial of MZE782 Result for PKU & CKD Treatment
11 Sep 2025 //
GLOBENEWSWIRE
Maze Therapeutics` $150M Private Placement Oversubscribed
11 Sep 2025 //
GLOBENEWSWIRE
Maze, Vertex Marketing Spat Escalates to Federal Regulators
28 Aug 2025 //
FIERCE PHARMA
Maze charts path through clinical development with planned IPO
07 Jan 2025 //
FIERCE BIOTECH
Maze finds its way to $115M series D
03 Dec 2024 //
FIERCE BIOTECH
Maze Therapeutics Starts Phase 1 Trial Of MZE782 For Kidney Disease
01 Oct 2024 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.